The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.
 
Chinmay Jani
No Relationships to Disclose
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
Archana Ajmera
No Relationships to Disclose
 
Arlene Araneta
No Relationships to Disclose
 
Christina Jamieson
No Relationships to Disclose
 
Edmund Folefac
No Relationships to Disclose
 
Arif Hussain
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Janssen Oncology; Merck
Research Funding - Bayer (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); FORMA Therapeutics (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Nektar (Inst); Orion (Inst); Pfizer (Inst); POINT Biopharma (Inst); Progenics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst)
 
Christos Kyriakopoulos
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Janssen Oncology; Sanofi
Research Funding - AstraZeneca; ESSA; Gilead Sciences; Pionyr; Sanofi
 
Adam C. Olson
Consulting or Advisory Role - RenovoRx
Research Funding - Reflexion Medical; Varian Medical Systems
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Exelixis; Natera; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Myovant Sciences (I)
Consulting or Advisory Role - Merck
Research Funding - Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Biren Saraiya
Honoraria - Eisai
Research Funding - Merck (Inst); Regeneron (Inst)
 
Salma K. Jabbour
Honoraria - Advarra; IMX Medical Reviewer; Merck; Novocure; Radialogica; syntactx
Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Beigene (Inst); Merck Sharp & Dohme (Inst); Natera (Inst); NCI (Inst)
 
S. Percy Ivy
No Relationships to Disclose
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; InVitae; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Neal Ian Lindeman
No Relationships to Disclose
 
Bose Kochupurakkal
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Artios; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Fusion Pharmaceuticals; ImmunoMet; Janssen Oncology; Kymera; Lilly; Merck Serono; Pfizer; Syros Pharmaceuticals; Xinthera; Zentalis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb/Medarex (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Cyclacel (Inst); Cyteir (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)